CZO.V - Ceapro Inc.
| Previous Close | 0.2800 |
| Open | 0.3000 |
| Bid | 0.2900 x 0 |
| Ask | 0.3000 x 0 |
| Day's Range | 0.2900 - 0.3000 |
| 52 Week Range | 0.2700 - 0.5000 |
| Volume | 33,000 |
| Avg. Volume | 31,465 |
| Market Cap | 22.427M |
| Beta (3Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0110 |
| Earnings Date | Nov. 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
How Much Did Ceapro Inc.'s (CVE:CZO) CEO Pocket Last Year?
Gilles Gagnon has been the CEO of Ceapro Inc. (CVE:CZO) since 2012. This analysis aims first to contrast CEO...
- GlobeNewswire
Ceapro Inc. Reports 2019 Third Quarter Financial Results and Operational Highlights
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery.
- GlobeNewswire
Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides
OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the European and U.S. Patent and Trademark Offices have issued the Company European Patent No. 2411527 and U.S. Patent No. 10,334,869 entitled, “Method For Increasing Concentration of Avenanthramides in Oats,” related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada. Ceapro's flagship product, avenanthramides, is a group of phenolic alkaloids compounds uniquely found in oats and produced using a proprietary patented process.
- GlobeNewswire
Ceapro Begins Trading on the OTCQX Best Market
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its common shares have been approved for trading onto the OTCQX® Best Market, a U.S. market that is operated by the OTC Markets Group in New York.
- Simply Wall St.
Did You Manage To Avoid Ceapro's (CVE:CZO) Devastating 80% Share Price Drop?
Ceapro Inc. (CVE:CZO) shareholders should be happy to see the share price up 13% in the last quarter. But only the...
- GlobeNewswire
Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that during a podium presentation, Dr. Bernhard Seifried, Senior Director, Engineering Research & Technologies at Ceapro, will present at the 3rd International Symposium on Pharmaceutical Engineering Research (“SPhERe”) being held September 25-27, 2019 in Braunschweig, Germany.
- GlobeNewswire
Ceapro Inc. to Present at the Fall Investor Summit in New York
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will present at the Fall Investor Summit on Monday, September 16, 2019 at 2:30 PM EDT in New York, NY. For more information about the conference, please click here to visit the conference website.
- GlobeNewswire
Ceapro Inc. Reports 2019 Second Quarter and Six-Month Financial Results and Operational Highlights
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development.
- GlobeNewswire
Ceapro Announces Research Funding Award from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada for Joint Projects with McMaster University
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded a $670,315 Collaborative Health Research Projects (CHRP) Initiative grant for a three-year collaborative project with Dr. Todd Hoare, Dr. Brian Coombes and Dr. Kjetil Ask at McMaster University. This project marks the beginning of the second phase of an extensive research program initiated in March 2016 with researchers at McMaster University under Dr. Hoare’s leadership.
- Simply Wall St.
Does Ceapro Inc. (CVE:CZO) Have A Particularly Volatile Share Price?
If you own shares in Ceapro Inc. (CVE:CZO) then it's worth thinking about how it contributes to the volatility of your...
- GlobeNewswire
Ceapro Inc. Announces Signing of a Contribution Agreement with National Research Council of Canada
EDMONTON, Alberta, Aug. 15, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
- Simply Wall St.
What Percentage Of Ceapro Inc. (CVE:CZO) Shares Do Insiders Own?
If you want to know who really controls Ceapro Inc. (CVE:CZO), then you'll have to look at the makeup of its share...
- GlobeNewswire
Ceapro Announces Results of 2019 Shareholders’ Meeting
EDMONTON, Alberta, June 10, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
- GlobeNewswire
Ceapro Presents Positive Results from Avenanthramides Study at the 2019 American Society of Sports Medicine Meeting
Ceapro Inc. (CZO.V) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented very promising data from its collaboration study of the immunoregulatory effect of oat avenanthramides during downhill running in young men and women at the Annual World Congress of the American College of Sports Medicine (ACSM), held May 28-June 1, 2019 in Orlando, Florida. The Company previously announced positive results on the anti-inflammatory properties of avenanthramides at the American Society for Nutrition’s inaugural flagship meeting, Nutrition 2018, which showed that oat avenanthramides supplementation reduces circulatory inflammation and inhibits expressions of chemokines and adhesion molecules.
- GlobeNewswire
Ceapro Inc. Commences Patient Enrollment in First-in-Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has commenced patient enrollment in its comparison study evaluating high-medium molecular weight beta glucan as an add-on therapy to statins in subjects with hyperlipidemia. “We are pleased with the progress of this important study and believe that it represents a significant milestone for the Company as we continue our transition towards becoming a biopharmaceutical company.
- GlobeNewswire
Ceapro Inc. Reports 2019 First Quarter Financial Results and Highlights
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development.
- GlobeNewswire
Ceapro Inc. Announces Receipt of Site License from Health Canada
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that both of its two Alberta-based bioprocessing plants, located in Leduc and Edmonton, have received a Site License from the Health Canada Natural and Non-Prescription Health Products Directorate. This license enables the Company to fabricate, package, label, release and distribute final products.
- Simply Wall St.
Does Ceapro Inc.'s (CVE:CZO) CEO Pay Compare Well With Peers?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Gilles Gagnon became the CEO of Ceapro Inc. (CVE:CZO) in 2012. This report will, first, ex...
- GlobeNewswire
Ceapro Inc. to Present at the ThinkEquity Conference in New York City
EDMONTON, Alberta, April 24, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
- GlobeNewswire
Ceapro Inc. Announces Positive Key Findings from Three Oral Presentations Given at European Meeting on Supercritical Fluids
EDMONTON, Alberta, April 15, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
- GlobeNewswire
Ceapro Inc. Reports Fourth Quarter and Full Year 2018 Results and Highlights
– 2018 marked by Company’s catalytic pivot from contract manufacturer tobiopharmaceutical company and validation of Ceapro’s dedication to innovation – EDMONTON, Alberta, April.
- GlobeNewswire
Ceapro Announces Acceptance of Abstract for Presentation at the 2019 American College of Sports Medicine Annual Meeting
EDMONTON, Alberta, March 27, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
- GlobeNewswire
Ceapro Inc. Announces Issuance of Indian Patent Application for Enabling Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Office of the Controller General of Patents, Design and Trademarks, India has issued the Company Patent No. 305103 entitled, “Supercritical Fluid Treatment of High Molecular Weight Biopolymers,” related to its Pressurized Gas eXpanded (“PGX”) technology.
- GlobeNewswire
Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)
EDMONTON, Alberta, Feb. 26, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.
- GlobeNewswire
Ceapro Announces 2019 Management Team and Grant of Stock Options and Restricted Share Units
Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) and restricted share units (“RSUs”) to all employees, officers and directors of the Company. Options to purchase 420,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an exercise price of $0.38.5 per common share. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant.
